Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 2008

View Archived Issues

Significant treatment effect seen with gepirone ER in depression studies

Link between metabotropic glutamate receptor and fragile X syndrome seen in mice

Brain cholesterol reduction with LXR agonist beneficial in experimental Niemman-Pick disease

Recent patents report novel anticancer agents

BioMarin and Genzyme restructure their joint venture for Aldurazyme for MPS I

Novel therapeutic compounds for metabolic disorders described in recent patent literature

Innocoll initiates dosing in U.S. phase II clinical trial of CollaRx bupivacaine surgical implant

Multifunctional serotonin receptor modulator suppresses psychosis and appetite in mice

Astellas Pharma reports third quarter 2007 results

Recent patents disclose new psychopharmacologic drugs

Pfizer and Taisho sign definitive agreement for novel schizophrenia drug candidate

Access acquires Somanta and adds four new anticancer compounds to pipeline

Biogen and Elan report on Tysabri safety in MS patients

Celldex receives fast track designation for glioblastoma vaccine CDX-110

Jazz Pharmaceuticals receives orphan drug designation for acute repetitive seizures candidate

Optimer awarded NIH grant to develop OPT-80 for hospital-associated infection

Orphan drug designation granted for non-radiolabeled TM-601

Sangamo initiates phase II clinical trial of SB-509 in diabetic neuropathy

Metabasis reports positive results from phase Ib clinical trial of MB-07811 for hyperlipidemia

R-7128 achieves rapid virologic response in 4-week combination study for HCV

Rib-X initiates two phase II studies of oxazolidinone antibiotic RX-1741 for CAP and uSSSI

Callisto restructures license agreement with Genzyme for atiprimod for carcinoid cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...